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showed well-organized background activity; paroxysmal abnor­
malities disappeared. This inborn biotinidase deficiency is one 
of the first treatable neurometabolic diseases in children.
Thursday, September 5, 1996
Parallel Session 3: Principles of Treatment
9:30 a.m. to 12:00 noon
High-Dose Gabapentin is Absorbed and Can Be Effective. E. A.
Wilson, G. Forrest, and M. J. Brodie (Epilepsy Research Unit, 
Western Infirmary, Glasgow, Scotland).
Oral absorption of gabapentin (GBP) has been suggested to 
begin to saturate at >l,800-mg daily doses. Patients with refrac­
tory epilepsy, in whom GBP was introduced, were started on 400 
mg daily for the first week of treatment, with further increments of 
400 mg until seizures were controlled or to the limit of tolerability. 
All patients had three-times-daily regimens. When possible, con­
comitant antiepiieptic drug (AED) therapy was reduced. Plasma 
GBP levels were measured by high-performance liquid chroma­
tography at the same time after dosing after every increment of 
1,200 mg daily. Mean circulating GBP concentrations (mg/L) at 
each dose level were as follows: 1,200 mg, 4.1; 2,400 mg, 8.6; 
3,600 mg, 13.2; 4,800 mg, 15.5; and 6,000 mg, 17.2. In 3 patients 
receiving GBP in <6,000-mg doses daily, concentrations contin­
ued to increase at each increment. However, the curves were 
not completely linear, indicating some reduction in relative 
bioavailability at high dosage. So far, 8 patients receiving 
2,400-6,000 mg GBP daily have shown improvement in seizure 
control >50% , with 2 becoming seizure-free. Their plasma GBP 
concentrations varied from 5.9 to 21.0 mg/L. Side effects most 
commonly reported included tiredness, dizziness, headache, and 
diplopia. Some patients developed flatulence and diarrhea, and 
a few others myoclonic jerks at GBP >3,600 mg/day. These 
problems responded rapidly to dosage reduction. High-dose GBP 
is absorbed and can be effective in controlling seizures in patients 
with refractory epilepsy.
Use of Intravenous Gammaglobulin in Drug-Resistant Epilepsy.
P. Tyomin, V. Perminov, A. Krapivkin, B. Belousova, and A. 
Ermakov (Institute of Pediatrics, Moscow, Russia).
Eight children aged 8 months to 6 years with resistant forms 
of epilepsy [Lennox-Gastaut syndrome (LGS), infantile spasms 
(IS)] and adequate anticonvulsant therapy received intravenous 
injections o f Sandoglobulin (Sandoz). The course consisted of 
three injections (on days 1, 15, and 36 of therapy); the single 
dose varied from 200 to 400 mg/kg per injection.
Improvement was noted in all 8 patients (100%), 5 children 
had complete seizure control, (62, 5%), and duration of remission 
was 3-10 months. During the control period (3-10 months), we 
observed no seizures recurrence in these children. Three patients 
(37.5%) had 50% reduction in number of seizures; this reduction 
was stable throughout the same control period. We noted no 
adverse reactions due to Sandoglobulin. Sandoglobulin treatment 
did not cause changes in immune status. The positive anticonvul­
sant effect observed in our study confirms the possibility of use 
of Sandoglobulin in drug-resistant epilepsy.
Effects of Chronic Diazepam on Absence-Like Phenomena and 
on the EEG on the WAG/Rij Rat. Clementina M. Van Rijn, 
Marijtje L. A . Jongsma, Peter M. Edelbroek, and Ris Dirksen 
(Departments of Psychology/NICI and Anaesthesiology, Univer­
sity of Nijmegen, The Netherlands).
We evaluated the effects of chronic diazepam (DZP) treatment 
for 21 days on spike-wave discharges (SWD) and on the spectral
content of the EEG of the WAG/Rij rat; a model for absence 
epilepsy. Permeable silastic tubes either empty or filled with DZP 
were implanted subcutaneously. The dose the animals received 
was —50 mg/kg/day, resulting in sustained constant blood con­
centrations. EEGs were recorded before implantation, during 
treatment, and 9 days after tube removal.
DZP reduced both the incidence and the duration of SWD. 
The magnitude of these effects decayed during the treatment: 
The incidence of the SWDs increased again with a half-life (t^) 
of 3 days; baseline values were not reached, however. The mean 
duration increased slowly with a ii of —20 days. The postlreat- 
ment measurement showed no group differences. DZP caused 
an increase in the power of the high-frequency band (21-40 Hz). 
This change persisted during the 21-day treatment and was no 
longer evident on the ninth day after tube removal.
The results show tolerance development to the antiabsence 
effect of DZP, but different t| values for different parameters. 
No tolerance developed to the effect of DZP on the spectral 
content of the EEG. These observations suggest that different 
molecular mechanisms underlie the genesis and the termination 
of the epileptic phenomena and that the incidence and the duration 
of the SWD are independent of changes in the spectral content 
of the EEG.
Behavior Seizure Control: Biofeedback and Behavior Therapy 
of Partial Epilepsy. Carmen Uhlmann, N. Birbaumer, and W. 
Frdscher (Zentrum fur Psychiatrie, Abteilung, Neurologie, Ra- 
vensburg, Germany).
In patients with partial seizures, drug resistance unfortunately 
is common. One possible strategy to help patients may be clinical- 
psychological treatment. Birbaumer et al. (1991) successfully 
treated patients with epilepsy, mostly with complex partial sei­
zures, with biofeedback of slow cortical potentials. In a multicen- 
ter study, we wish to verify the results of this first study in a 
greater number of patients and to determine the patients in whom 
the biofeedback method is most promising. Drug resistance was 
defined as ineffectiveness of two standard antiepileptic drugs 
administered as mono- or combination therapy in 2 years.
In our center, 10 patients were recruited in the past year, with
5 in the slow-wave group and 5 in the control group. The verum 
group is treated with slow-wave biofeedback and behavioral mod­
ification elements. The controls receive breathing biofeedback 
(percentage of end tidal~C02 and respiration rate) and behavior 
therapy. All patients are treated for 3 months.
The study design and treatment elements are presented, and 
preliminary results of biofeedback acquisition and changes in 
seizure frequency (in both groups) in s  1-year follow-up are re­
ported. The results are encouraging in some patients. (Supported 
by Deutsche Forschungsgemeinschaft Fr 645/3-1.)
Assessment of Antiepileptic Drug Interaction by Ictal Behavior 
Analysis. O. E. Della Paschoa, R. Hamstra, R. A. Voskuyl, 
M. R. Kruk, and M. Danhof (Division of Pharmacology, Leiden/ 
Amsterdam Center for Drug Research, Leiden, The Nether­
lands).
Reports on pharmacodynamic antiepileptic drug (AED) inter­
action in vivo are scarce and conflicting. The current approaches 
for the assessment of anticonvulsant effect are not focused on 
the exact discrimination of drug action on the clinical patterns 
of seizure activity. Recently, quantitative behavioral analysis was 
shown to be a useful tool for the characterization of ictal and 
postictal seizure components in the cortical stimulation model. 
We applied this approach to identify drug-induced changes in the 
pattern of overt motor seizure, characterizing the interaction 
between phenytoin (PHT) and valproate (VPA) by ictal behavior 
analysis, in parallel with determination of the concentration- 
anticonvulsant effect profile. Eighteen male Wistar-derived rats 
were allocated to three groups according to a parallel-group de-
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